These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 33941922)

  • 1. Evolution of delayed resistance to immunotherapy in a melanoma responder.
    Liu D; Lin JR; Robitschek EJ; Kasumova GG; Heyde A; Shi A; Kraya A; Zhang G; Moll T; Frederick DT; Chen YA; Wang S; Schapiro D; Ho LL; Bi K; Sahu A; Mei S; Miao B; Sharova T; Alvarez-Breckenridge C; Stocking JH; Kim T; Fadden R; Lawrence D; Hoang MP; Cahill DP; Malehmir M; Nowak MA; Brastianos PK; Lian CG; Ruppin E; Izar B; Herlyn M; Van Allen EM; Nathanson K; Flaherty KT; Sullivan RJ; Kellis M; Sorger PK; Boland GM
    Nat Med; 2021 Jun; 27(6):985-992. PubMed ID: 33941922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects.
    Li W; Gu J; Fan H; Zhang L; Guo J; Si L
    Crit Rev Oncol Hematol; 2024 Sep; 201():104426. PubMed ID: 38908767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
    Haugh AM; Salama AKS; Johnson DB
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
    Boshuizen J; Vredevoogd DW; Krijgsman O; Ligtenberg MA; Blankenstein S; de Bruijn B; Frederick DT; Kenski JCN; Parren M; Brüggemann M; Madu MF; Rozeman EA; Song JY; Horlings HM; Blank CU; van Akkooi ACJ; Flaherty KT; Boland GM; Peeper DS
    Nat Commun; 2020 Aug; 11(1):3946. PubMed ID: 32770055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding genetic determinants of resistance to immune checkpoint blockers.
    Aspeslagh S; Chabanon RM; Champiat S; Postel-Vinay S
    Semin Cancer Biol; 2020 Oct; 65():123-139. PubMed ID: 31881338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
    Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
    Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.
    Akiyama Y; Kiyohara Y; Yoshikawa S; Otsuka M; Kondou R; Nonomura C; Miyata H; Iizuka A; Ashizawa T; Ohshima K; Urakami K; Nagashima T; Kusuhara M; Sugino T; Yamaguchi K
    Oncol Rep; 2018 Mar; 39(3):1125-1131. PubMed ID: 29286146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma.
    Sheng Y; Tong L; Geyu L
    Int Immunopharmacol; 2020 Nov; 88():106921. PubMed ID: 32871477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

  • 11. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
    Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA
    Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade.
    Sahni S; Wang B; Wu D; Dhruba SR; Nagy M; Patkar S; Ferreira I; Day CP; Wang K; Ruppin E
    Nat Commun; 2024 Oct; 15(1):8867. PubMed ID: 39402030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15
    Dominguez CX; Müller S; Keerthivasan S; Koeppen H; Hung J; Gierke S; Breart B; Foreman O; Bainbridge TW; Castiglioni A; Senbabaoglu Y; Modrusan Z; Liang Y; Junttila MR; Klijn C; Bourgon R; Turley SJ
    Cancer Discov; 2020 Feb; 10(2):232-253. PubMed ID: 31699795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Biomarkers for Melanoma Immunotherapy.
    Twitty CG; Huppert LA; Daud AI
    Curr Oncol Rep; 2020 Feb; 22(3):25. PubMed ID: 32048065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
    Zeng H; Jiang Q; Zhang R; Zhuang Z; Wu J; Li Y; Fang Y
    Sci Rep; 2024 Oct; 14(1):22872. PubMed ID: 39358546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
    Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
    Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.